Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Ixekizumab reduces erosion and increases backfill in the sacroiliac joints of patients with radiographic axial ...

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

Botulinum toxin type A may help reduce inflammation in hidradenitis suppurativa (HS) by inhibiting mast cell degranulation.

A total of 118 recommendations based on expert consensus were published regarding the treatment of hidradenitis suppurativa ...

Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., ...

Manufacturing: As a result of FDA approval of RYONCIL in December 2024, the US$23.0 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now ...

The global Psoriatic Arthritis (PsA) Treatment Market is expected to grow from USD 11,973.7 million in 2024 to USD 25,375.6 ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...

Penn Medicine used an artificial intelligence tool to find a treatment that aided in saving the life of a patient with ...

Interdisciplinary collaboration is key to reducing the risk for osteonecrosis of the jaw and improving patient care.

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with Crohn's disease.